Safety and Efficacy of Romiplostim in Treatment of Chronic ITP in Children
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 18
SponsorAssiut University
About this trial
The aim is to evaluate safety and efficacy of Romiplostim in the treatment of chronic ITP in children
Eligibility criteria
Qualifiers
Patients aged between 1 and 18 years
Diagnosis of chronic ITP
Refractory to or intolerant of first-line therapies (e.g.corticosteroids , intravenous immunoglobulin [ IVIG ] , and oral eltrombopag )
Platelet count<30,000/µL, or evidence of bleeding or risk of bleeding with platelet count<50,000/µL.
Disqualifiers
Evidence of secondary thrombocytopenia (e.g., HIV, HCV, systemic lupus erythematosus)
congenital thrombocytopenia
Age < 1year or more than 18 years
Aplastic anemia
Trial design
Treatments tested in this trial
- Safety and efficacy of Romiplostim in Treatment of chronic ITP in children
Treatment groups
No treatment groups listed
Locations
Sponsors and collaborators
Source ClinicalTrials.gov